Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin FCR Early-Stage Breast Cancer
NCT07909408Phase 2Not yet recruiting
- Sponsor
- NYU Langone Health
- Start
- Jan 2027
- Primary completion
- Jan 2031
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in Fear of Cancer Recurrence (FCR), anxiety disorder and major depressive disorder (MDD) (2 arms), sponsored by NYU Langone Health. Primary endpoint: Fear of Cancer Recurrence Inventory-Short Form at 4 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
Fear of Cancer Recurrence (FCR)anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07909408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07909408.